 |
 Video: What is a Stock Split?
|
|
|
| Iovance Biotherapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of of cell therapies as cancer immunotherapy products. Co.'s key product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition, Co. is investigating the effectiveness and safety of tumor infiltrating lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer, and peripheral blood lymphocyte therapy for treatment of chronic lymphocytic leukemia through its sponsored trials, as well as in other oncology indications through collaborations. According to our Iovance Biotherapeutics stock split history records, Iovance Biotherapeutics has had 0 splits. | |
|
Iovance Biotherapeutics (IOVA) has 0 splits in our Iovance Biotherapeutics stock split history database.
Looking at the Iovance Biotherapeutics stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Iovance Biotherapeutics shares, starting with a $10,000 purchase of IOVA, presented on a split-history-adjusted basis factoring in the complete Iovance Biotherapeutics stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
08/21/2012 |
|
| End date: |
08/18/2022 |
|
| Start price/share: |
$0.45 |
|
| End price/share: |
$12.38 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
2,651.11% |
|
| Average Annual Total Return: |
39.31% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$275,060.64 |
|
| Years: |
10.00 |
|
|
|
|
|
